-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 19, 2021, Nevro announced that its proprietary 10 kHZ spinal cord stimulation (SCS) "Senza" system has been approved by the US FDA for the treatment of chronic pain caused by painful diabetic neuropathy (PDN)
According to estimates by the World Health Organization (WHO), there are currently approximately 422 million adult diabetic patients in the world, and the prevalence (8.
In April 2021, the randomized controlled SENZA-PDN trial of the Senza Spinal Cord Stimulation System showed that it can safely provide effective treatment for patients with refractory PDN
In addition, at the 81st Scientific Meeting of the American Diabetes Association (ADA) held in June 2021, Nevro announced the trial’s 12-month follow-up results and 6-month crossover patient data
Note: The original text has been deleted
Reference materials:
[1] Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN).
[2] Petersen, E.
